|
Fibroblast growth factor 21 and chemerin level of serum in heart failure patients in Semnan province
|
Ghazaleh Assar   , Bahador Bagheri |
|
|
|
Abstract: (247 Views) |
Introduction: Heart failure (HF) is a life-threatening disease, and it can be caused by a variety of causes, including ischemic, hypertension, and inflammatory heart disease. Fibroblast growth factor 21 (FGF21) is a peptide hormone that regulates the homeostasis of lipids and glucose. In recent years, FGF21 has been indicated as a biomarker for heart failure. Also, chemerin is a new adipocytokine that induces apoptosis in cardiomyocytes and has been associated with cardiovascular disease. The aim of this study was to investigate the serum levels of FGF21 and chemerin in heart failure patients in comparison to healthy subjects.
Methods and Materials: In this case-control study, twenty patients with heart failure as the case groups and twenty healthy subjects as the control groups in Semnan province were investigated. The serum levels of FGF21 and chemerin in both groups were measured using the ELISA method. The study with ethics code IR.SEMUMS.REC.1399.177 was approved by the ethics committee of Semnan University of Medical Sciences.
Results: The serum FGF21 levels were 217.25±39.35 IU/ml in HF patients and 194.8±35.63 IU/ml in healthy subjects. Also, the serum chemerin levels were 1543/63±480/80 IU/ml in HF patients and 1410/23±639/95 IU/ml in healthy subjects. There was a significant but not statistically significant difference observed between the mean serum levels of fibroblast growth factor 21 in the two groups in chronic kidney disease, diabetes mellitus, hyperlipidemia, blood pressure. Subgroup analysis showed that using angiotensin-converting enzyme inhibitors, metformin, spironolactone, and atorvastatin did not decrease the fibroblast growth factor 21 serum level.
Conclusion: In this study, there has not been a significant correlation between serum chemerin levels and HF, but there is a significant relationship between serum FGF21 levels and heart failure. Serum FGF21 is elevated in HF, and it may offer potential therapeutic strategies for cardiac disease. Furthermore, common drugs used by heart failure patients did not result in a decrease in the two biomarker levels.
|
|
| Keywords: Heart failure, Fibroblast growth factor 21, Chemerin, ELISA |
|
|
Full-Text [PDF 260 kb]
(27 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/02/18 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
